Silence Therapeutics Set to Unveil Phase 2 Trial Results for Divesiran in Polycythemia Vera
Event summary
- Silence Therapeutics will host a conference call and webcast on August 10, 2026, at 8:00 a.m. EDT to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV).
- Divesiran is an siRNA therapy developed using Silence Therapeutics' mRNAi GOLD™ platform.
- The company focuses on precision-engineered medicines for rare and common diseases with high unmet medical needs.
The big picture
Silence Therapeutics' upcoming disclosure of Phase 2 trial results for divesiran marks a critical juncture in the development of siRNA-based treatments for polycythemia vera. The outcome will not only influence investor sentiment but also shape the strategic direction of the company within the broader biotech sector, particularly as it competes with other firms advancing novel RNA therapies.
What we're watching
- Clinical Efficacy
- How the topline results from the Phase 2 SANRECO trial will impact the perceived efficacy and safety profile of divesiran in treating polycythemia vera.
- Regulatory Pathway
- Whether positive results could accelerate regulatory approval processes or pave the way for further clinical trials.
- Market Positioning
- The pace at which Silence Therapeutics can leverage these results to strengthen its position in the competitive landscape of siRNA therapies.
Related topics